Table 6 Cohort studies of patients with renal infarction
From: Renal arteriography with endovascular ultrasound for the management of renal infarction patients
Study (number of patients) Period of inclusion | Mean age (Years) | History of atrial fibrillation (%) | ESRD | All-cause mortality rate | Recurrence of thromboembolic event | Antithrombotic secondary prevention treatment | ||
|---|---|---|---|---|---|---|---|---|
anticoagulant alone | antiplatelet alone | anticoagulant and antiplatelet | ||||||
Bourgaultet al. [10] 1989–2011 | 53 | 18 | 5% at 30 days | 0% at 30 days | – | 38 | 35 | 0 |
Huanget al. [3] 1991–2016 | 56 | 56 | 7%bat 48 months | 30% at 48 months | 12% at 48 months | 44 | 0 | 0 |
Ohet al. [15] 1993–2013 | 60 | 45 | 2,1% at 20 months | 5% at 20 months | 2,8 | 48,2 | 37,2 | 14 |
Baeet al. [12] 1995–2012 | 59 | 40 | – | – | – | 70 | 6 | 0 |
Mesianoet al. [13] 1999–2015 | 59,8 | 28 | 5.6% at 15 months | – | – | 44 | 33 | 0 |
Rheeet al. [1] 2000–2009 | 56 | 25 | – | 19,7% at 40 months | – | – | – | – |
Fauconet al. [11] 2000–2015 | 53 | 4 | – | – | – | – | – | – |
Yun [2] 2006–2012 | 61,3 | 53 | 2% at 41 months | 36% at 5 yearsa | 19% at 20 months | 100 (for 3–6 months and lifelong if indication) | 0 | 0 |
Cerba et al. [14] 2013–2015 | 57 | – | 0% at 6 months | 9% at 6 months | 0 at 6 months | 64 | 36 | 0,9 |
Erenet al. [16] 2015–2018 | 53 | 30 | 3% at 14 months | 5% at 14 months | – | 41 | 0 | – |